Shandong Xinhua Pharmaceutical Ends Equity Acquisition Talks with NovoSana
I'm PortAI, I can summarize articles.
Shandong Xinhua Pharmaceutical Company Limited has terminated its equity acquisition talks with NovoSana (Europe) B.V. due to an inability to reach a consensus on the agreement's terms. The company confirmed that this decision will not impact its current operations or development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments